Nuvectis CEO Expects FDA To Demand A New U.S. Study Of Its China-Approved PNH Pill

Ron Bentsur says a U.S. trial of ciprocopan is the realistic outcome, with an update on the FDA path due by year end.

Share
Nuvectis CEO Expects FDA To Demand A New U.S. Study Of Its China-Approved PNH Pill

Nuvectis Pharma CEO Ron Bentsur said on the company's third-quarter earnings call Wednesday that he expects the FDA to require a new U.S. study of ciprocopan, its once-daily pill for PNH that is already approved in China. "Realistically, we believe that we're going to have to run a study," he said.

From two trials to none

Bentsur, Nuvectis's chairman and chief executive, described the range of outcomes as bookends. At one end the FDA asks for two trials, one in patients never treated with complement inhibitors and one in previously treated patients. Whichever reads out first would support the approval application, and the second would become a supplement. At the other end, it asks for none.

He said the company has a strong statutory case but that policy concerns, including not wanting to open the floodgates to drugs coming in from China, could weigh on the agency. The company is "gearing up internally" and waiting for "final marching orders" from the FDA, he said, and nothing is final.

If a study is required, Bentsur said, a single-arm trial would enroll about 35 patients and a controlled one roughly 70, in line with the China trials and the studies of Novartis's Fabalta. He said the company has established good contact with key opinion leaders and top U.S. recruiting sites from prior studies, with new hires including Dr. Dustin Little, head of the complement program, helping.

What the FDA asked in September

The first formal exchange with the FDA on PNH came in late September, Bentsur said. The agency asked whether the transfusion protocol in the China trials matched U.S. guidelines and the Fabalta studies. He said the criteria were pretty much identical and that the company put those concerns to bed.

He also argued that about 40% of patients in the two Fabalta phase three trials were Asian and that one was run entirely outside the U.S. He added that ciprocopan is an analog of Fabalta, built for a longer half-life. A U.S. regulatory update is due by year end.

A late-stage pivot with $140 million

Nuvectis, a clinical-stage cancer drug developer, closed a licensing deal with Haisco for ex-China rights to ciprocopan, also called NXP100, and to NXP200 in late June. It then raised $150 million in gross proceeds in a follow-on offering. It also placed about $37 million through its at-the-market facility in the third quarter.

The company ended the quarter with about $140 million in cash, which it expects to fund operations into the second half of 2029. The quarter's net loss was $30.1 million. Excluding the upfront license payment, a one-time NXP900 milestone and non-cash stock compensation, the adjusted net loss was $5.8 million.

China approved ciprocopan in July for patients not previously treated with complement inhibitors. Bentsur said approval for previously treated patients is expected in the first quarter of 2027. He put the PNH market at about $5 billion today, expected to double within 8 to 10 years.

NXP200, "a complete sleeper"

Asked about NXP200, a BRAF inhibitor for BRAF-mutated solid tumors, Bentsur called it "a complete sleeper" that no one is paying attention to. At the ESMO conference, a 27-patient China study showed a 40% response rate in 20 high-grade glioma patients, and 42.9% in the low-grade group.

More solid-tumor data from China is due in early 2027. Nuvectis plans U.S. applications to start human trials of NXP100 and NXP200 by year end, with a U.S. NXP200 trial targeted for early 2027.

Bentsur said the next word from the FDA on the U.S. path for ciprocopan should come before year end.

Sources

More on Nuvectis Pharma

All Nuvectis Pharma (NVCT) coverage →